William E. Rote - Concepedia

Concepedia

Author

William E. Rote

University of Michigan

Also Known As

W E Rote, W ROTE, W. E Rote, W. E. ROTE, W.E. Rote, William E Rote, William E. Rote, William Rote, William E. Rote

40

Publications

2.4K

Citations

24

H-Index

60

Concepts

All Affiliations

University of Michigan Amsterdam UMC Location University of Amsterdam University of Washington University of Leicester University of Groningen

WE

About

William E. Rote is an author at University of Michigan specializing in medicine, thrombosis, and vascular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	1.4K
2	Biochemistry	3	3	130
3	Natural Sciences	2	2	63
4	Health Sciences	1	1	197
5	Allergy	1	1	22

William E. Rote

×

34

Publications

2.4K

Citations

24

H-Index

	Year	Citations
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Thomas W. Geisbert, Lisa E. Hensley, Peter B. Jahrling, The Lancet Rhesus MonkeysPathogenesisViral PathogenesisImmunologyAntiviral Drug Development	2003	381
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, The Lancet	2023	224
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers, The Lancet GlomerulonephritisActive-controlled Clinical TrialRenal FunctionKidney FailureChronic Kidney Disease	2023	203
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Todd Hembrough, Glenn M. Swartz, Adonia E. Papathanassiu, PubMed ImmunologyTumor BiologyThrombosisAngiogenesisCoagulation Inhibitors	2003	197
Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement Agnes Lee, Giancarlo Agnelli, Harry Büller, Circulation	2001	166
Neutrophil inhibitory factor is neuroprotective after focal Ischemia in rats Ning Jiang, Matthew Moyle, Howard R. Soule, Annals of Neurology ImmunologyCell DeathFocal Cerebral IschemiaOxidative StressNeuroinflammation	1995	152
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix Arno H. Moons, Ron J.G. Peters, Nick R. Bijsterveld, Journal of the American College of Cardiology Percutaneous Coronary InterventionThrombosisElective Coronary AngioplastyappendixCardiovascular DiseasePharmacology	2003	98
Activation of Coagulation by Administration of Recombinant Factor VIIa Elicits Interleukin 6 (IL-6) and IL-8 Release in Healthy Human Subjects Evert de Jonge, Philip W. Friederich, George P. Vlasuk, Clinical and Vaccine Immunology ImmunologyImmune RegulationPathologyImmune SystemInflammation	2003	97
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, New England Journal of Medicine	2023	94
Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects Philip W. Friederich, Marcel Levi, Kenneth A. Bauer, Circulation	2001	81

Page 1